Back to Authors

Goadsby, Peter J.

https://orcid.org/0000-0003-3260-5904

A5004525209 | I34931013

Mayo Clinic

National Institute for Health and Care Research

Citations 73

International Classification of Headache Disorders-4 – Work in Progress 1

Cephalalgia | February 22, 2024 | Volume: 44 | Issue: 2 | Pages: No page available

10.1177/03331024241233937 | PMID 38388354

Efficacy of Erenumab for the Treatment of Patients With Chronic Migraine With and Without Aura (S32.006)

Neurology | December 7, 2023 | Volume: 90 | Issue: 15_supplement | Pages: No page available

10.1212/wnl.90.15_supplement.s32.006

Efficacy of Two Dose Regimens of Subcutaneous Fremanezumab Versus Placebo for the Preventive Treatment of Chronic Migraine (S32.005)

Neurology | December 7, 2023 | Volume: 90 | Issue: 15_supplement | Pages: No page available

10.1212/wnl.90.15_supplement.s32.005

Efficacy Of Fremanezumab in Patients With Chronic Migraine With or Without Concomitant Use of Preventive Medication (P4.099)

Neurology | December 7, 2023 | Volume: 90 | Issue: 15_supplement | Pages: No page available

10.1212/wnl.90.15_supplement.p4.099

Efficacy and Safety of 2 Dose Regimens of Subcutaneous Administration of Fremanezumab Versus Placebo for the Preventive Treatment of Episodic Migraine (P4.093)

Neurology | December 7, 2023 | Volume: 90 | Issue: 15_supplement | Pages: No page available

10.1212/wnl.90.15_supplement.p4.093

Orally Administered Atogepant Was Efficacious, Safe, and Tolerable for the Prevention of Migraine: Results From a Phase 2b/3 Study (S17.001)

Neurology | December 7, 2023 | Volume: 92 | Issue: 15_supplement | Pages: No page available

10.1212/wnl.92.15_supplement.s17.001

A Placebo-Controlled Study of Galcanezumab in Patients with Episodic Cluster Headache: Results from the 8-Week Double-Blind Treatment Phase (Plen02.004)

Neurology | December 7, 2023 | Volume: 92 | Issue: 15_supplement | Pages: No page available

10.1212/wnl.92.15_supplement.plen02.004

Ubrogepant is Effective for the Acute Treatment of Migraine in Patients with an Insufficient Response to Triptans (P3.10-024)

Neurology | December 7, 2023 | Volume: 92 | Issue: 15_supplement | Pages: No page available

10.1212/wnl.92.15_supplement.p3.10-024

Prevention of Episodic Migraine with AMG 334, a Human Anti-Calcitonin Gene-Related Peptide Receptor Monoclonal Antibody: Phase 2 Study Results and 52-Week Analysis of Open-Label Extension (S26.002)

Neurology | December 7, 2023 | Volume: 86 | Issue: 16_supplement | Pages: No page available

10.1212/wnl.86.16_supplement.s26.002

Prevention of Episodic Migraine with AMG 334, a Human Anti-Calcitonin Gene-Related Peptide Receptor Monoclonal Antibody: Phase 2 Study Results and 52-Week Analysis of Open-Label Extension (I3.001)

Neurology | December 7, 2023 | Volume: 86 | Issue: 16_supplement | Pages: No page available

10.1212/wnl.86.16_supplement.i3.001